The Efficacy and Safety of Ormeloxifene in Dysfunctional Uterine Bleeding

The Efficacy and Safety of Ormeloxifene in Dysfunctional Uterine Bleeding

The study was undertaken to assess the efficacy, safety and acceptability of ormeloxifene in the medical management of Dysfunctional Uterine Bleeding (DUB). Sixty women with DUB were given ormeloxifene 60mg twice a week for 12 weeks and once a week for next 12 weeks. Follow up was done at 3 and 6 months. The primary outcome measures were menstrual blood loss, hemoglobin concentration and endome...

A Study of Ormeloxifene in Case of Dysfunctional Uterine Bleeding

Background: Menorrhagia accounts for 12% of all gynaecology consultations and is one of the most common causes of iron deficiency anaemia in females after nutritional anaemia. Objectives: To evaluate the efficacy and side effects of ormeloxifene in cases of dysfunctional uterine bleeding. Material and Methods: 30 women aged 28-46 years who attended the outpatient gynaecology department in a ter...

A study of efficacy of ormeloxifene in the pharmacological management of dysfunctional uterine bleeding.

OBJECTIVE This study was carried out to evaluate the efficacy of Ormeloxifene in the pharmacological management of dysfunctional uterine bleeding. DESIGN AND SETTING A prospective study was conducted on women with dysfunctional uterine bleeding, who attended to out - patient department of Obstetrics & Gynaecology in a tertiary care general hospital. MATERIAL AND METHODS Women with DUB were ...

Clinco-Pathological Patterns in Women with Dysfunctional Uterine Bleeding

Background: The term dysfunctional uterine bleeding(DUB) refers to any abnormal bleeding from the uterus, unassociated with tumour, inflammation and pregnancy. The histological diagnosis of DUB is very essential for adequate management especially in perimenopausal and postmenopausal females. The present study was undertaken with the aim of evaluating DUB in various age groups, carry out histopa...

The management of dysfunctional uterine bleeding.